Yellow fever vaccination: Update on rare and severe adverse effects;Vaccination antiamarile : mise au point à propos des effets indésirables rares et graves

Medecine et Maladies Infectieuses

Volumn 39, Issue 4, 2009, Pages 234-241

  Receveur, M C ^a   Bruyand, M ^a   Pistone, T ^a   Malvy, D ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Vaccine adverse events; Yellow fever vaccine

Indexed keywords

STAMARIL; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ARBOVIRUS; BRONCHITIS; DIARRHEA; DRUG HYPERSENSITIVITY; ENDEMIC DISEASE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNIZATION; INFECTION PREVENTION; MEDICAL RESEARCH; OSTEOARTHRITIS; RHEUMATIC FEVER; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT SURVEY; THYMUS DISEASE; TRACHEOBRONCHITIS; TREATMENT OUTCOME; VACCINATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ARTICLE; HOSPITALIZATION;

HUMANS; SEVERITY OF ILLNESS INDEX; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 64749083814     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2008.11.013     Document Type: Short Survey

References (52)

1. Anonymous. Yellow fever vaccine. WHO position pape. Wkly Epidemiol Rec 78 (2003) 349-359
2. Robertson S.E., Hull B.P., Tomori O., Bele O., LeDuc J.W., and Esteves K. Yellow fever: a decade of reemergence. JAMA 276 (1996) 1157-1162
3. Rodhain F. Le mystère des épidémies. 2005 : Paris, Éditions Pasteur.
4. Anonymous. Progress in the control of yellow fever in Africa. Wkly Epidemiol Rec 80 (2005) 50-55
5. Formenty P., Roth C., Gonzalez-Martin F., Grein T., Ryan M., Drury P., et al. Les pathogènes émergents, la veille internationale et le règlement sanitaire international (2005). Med Mal Infect 36 (2006) 9-15
6. Fitzner J., Coulibaly D., Kouadio D.E., Yavo J.C., Loukou Y.G., Koudou P.O., et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 23 (2004) 156-162
7. Akoua-Koffi C., Ekra K.D., Kone A.B., Dagnan N.S., Akran V., Kouadi K.L., et al. Detection and management of the yellow fever epidemic in the Ivory Coast. Med Trop 62 (2002) 305-309
8. Anonymous. Yellow fever situation in Africa and South America, 2005. Wkly Epidemiol Rec 81 (2006) 317-324
9. Huhn G.D., Brown J., Perea W., Berthe A., Otero H., Libeau G., et al. Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons, Liberia, 2004. Vaccine 24 (2006) 730-737
10. Barnett E.D. Yellow fever: epidemiology and prevention. CID 44 (2007) 850-856
11. Monath T.P., and Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34 (2002) 1369-1378
12. Bae H.G., Drosten C., Emmerich P., Colebunders R., Hantson P., Pest S., et al. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J Clin Virol 33 (2005) 274-280
13. Fatal yellow fever in a traveller returning from Amazonas, Brazil, 2002. JAMA 2002;287:2499-2500.
14. Dos Santos C.N., Post P.R., Carvalho R., Ferreira I.I., Rice C.M., and Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 35 (1995) 35-41
15. Reinhardt B., Jaspert R., Niedrig M., Kostner C., and L'Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56 (1998) 159-167
16. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., and Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59 (1981) 895-900
17. Niedrig M., Lademann M., Emmerich P., and Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4 (1999) 867-871
18. Stamaril. http://www.aventis-pasteur-msd.fr/datavax/produits/stamaril.htm (site consulté en mars 2006).
19. Contrôle de l'immunité antiamarile, http://www.pasteur-cerba.com/index.htm (site consulté en mars 2006).
20. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 (2001) 98-104
21. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358 (2001) 91-97
22. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., and Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358 (2001) 121-122
23. Marfin A.A., Eidex R.S., Kozarsky P.E., and Cetron M.S. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 19 (2005) 151-168
24. Bae H-G, Domingo Carrasco C, Tenorio A, Teuwen D, Niedrig M. Analysis of adverse events after yellow fever vaccine 17D (abstract). Annual Meeting of the Gesellschaft für Virologie, München, Germany, 2006.
25. Marianneau P., Georges-Courbot M., and Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 358 (2001) 84-85
26. Cetron M.S., Marfin A.A., Julian K.G., Gubler D.J., Sharp D.J., Barwick R.S., et al. Yellow Fever Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR 51 (2002) 1-11
27. Galler R., Pugachev K.V., Santos C.L.S., Ochran S., Jabor A.V., Rodrigues S.G., et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine virus associated with serious adverse events in Brazil. Virololgy 290 (2001) 309-319
28. Barrett ADT, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever Vaccines: new insights, a report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005. Vaccine 2007;25:2758-65.
29. Vasconcelos P.F.C., Bryant J.E., Travassos da Rosa P.A., Tesh R.B., Rodrgues S.G., and Barrett A.D.T. Genetic divergence and dispersal of yellow fever virus. Braz Emerg Infect Dis 10 (2004) 1578-1584
30. Engel A.R., Vasconcelos P.F.C., McArthur M.A., and Barrett A.D.T. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 24 (2006) 2803-2809
31. Legros F, Leroy JP, Nasst N, Saluzzo JF, de Gentile L, Teuwen D. Fièvre jaune, épidémiologie et prévention vaccinale du voyageur. Bull. Epidemiol. Hebdo 2007;236-238:25-26
32. Khromava A.Y., Barwick Eidex R., Weld L.H., Hohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23 (2005) 3256-3263
33. Lawrence G.L., Burgess M.A., and Kass R.B. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 28 (2004) 244-248
34. Barwick Eidex R., and for the yellow fever vaccine safety working group. History of thymoma and yellow fever vaccination. Lancet 364 (2004) 936 [Letter to the Editor]
35. Filippis de A.M.B., Nogueira R.M.R., Jabor A.V., Schatzmayr H.G., Oliveira J.C., Dinis S.C.M., et al. Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil. Vaccine 22 (2004) 1073-1078
36. Doblas A., Domingo C., Bae H.G., Bohórquez C.L., de Ory F., Niedrig M., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain: case report. J Clin Virol 36 (2006) 156-158
37. Anonymous. Adverse events associated with 17D-derived yellow fever vaccination. United States, 2001-2002. MMWR 51 (2002) 989-993
38. Monath T. In: Vaccines Plotkin S., and Orenstein W. (Eds). Yellow fever. 4th ed. (2004), WB Saunders, Philadelphia 1095-1176
39. Anonymous. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA 198 (1966) 671-672
40. Kengsakul K., Sathirapongsasuti K., and Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85 (2002) 131-134
41. Jennings AD, C Gibson CA, Miller BR, Mathews JH, Mitchell CJ, Roehrig JT, et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 1994;169:512-8.
42. Kelso J.M., Mootrey G.T., and Tsai T.F. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 103 (1999) 698-701
43. Barban V., Girerd Y., Aguirre M., Gulia S., Petiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine 25 (2007) 2941-2950
44. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, Arilvax. Vaccine 22 (2004) 2103-2105
45. Troillet N., and Laurencet F. Effects of yellow fever vaccination. Lancet 358 (2001) 1908-1909 [letter to the Editor]
46. e Journées de pharmacovigilance, Joint meeting with pharmacological societies of Brazil and Portugal, April 2002.
47. Adhiyaman V., Oke A., and Cefai C. Effects of yellow fever vaccination. Lancet 358 (2001) 1907-1908 [letter to the Editor]
48. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribiero J.G.L., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 132 (2004) 939-946
49. Werfel U., and Popp W. Effects of yellow fever vaccination. Lancet 358 (2001) 1909 [letter to the Editor]
50. Gerasimon G., and Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease; case report. South Med J 98 (2005) 653-656
51. Zhou X., Liu D., Shi Y., Long Y., Li D., Liu H., et al. Adverse effects of attenuated yellow fever vaccine with multiple organ injury - a case report. Chin Med J 85 (2005) 936
52. Muñoz J, Villella A, Domingo C, Nicolas JM, de Ory F, Corachan M et al. Yellow fever-associated viscerotropic disease in Barcelano, Spain. J Trav Medicine 2008;15:202-5.